The sympathomimetic agonist mirabegron did not lower JAK2-V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: results of phase II study SAKK 33/14. (2019)
Attributed to:
Wellcome Trust MRC Cambridge Stem Cell Institute
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.3324/haematol.2018.200014
PubMed Identifier: 30409796
Publication URI: http://europepmc.org/abstract/MED/30409796
Type: Journal Article/Review
Volume: 104
Parent Publication: Haematologica
Issue: 4
ISSN: 0390-6078